The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer-Reference-Cited by-同舟云学术

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

Published:2013-01 Issue:1-2 Volume:206 Page:26-31
ISSN:2210-7762
Container-title:Cancer Genetics
language:en
Short-container-title:Cancer Genetics

Author:

Fiala Ondrej,Pesek Milos,Finek Jindrich,Benesova Lucie,Belsanova Barbora,Minarik Marek

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology

Reference42 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. EGFR-mutated lung cancer: a paradigm of molecular oncology;Zhang;Oncotarget,2010

4. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer;Sequist;J Clin Oncol,2007

5. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making;Gandara;Clin Lung Cancer,2009

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in India;ecancermedicalscience;2024-02-22

2. An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health;Applied Biochemistry and Biotechnology;2023-10-28

3. Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022);Pharmaceuticals;2023-08-15

4. The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia;F1000Research;2023-06-15

5. Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer;Frontiers in Genetics;2022-10-21